CNBDA

Overview

CNBDA is a selective SHP2 inhibitor with an IC 50 of 5 μM. CNBDA binds to the active site of SHP2 through interactions with surrounding positively charged and polar amino acids , inhibits the PTPase activity of SHP2 , and blocks the autodephosphorylation of SHP2 . CNBDA inhibits the transformed phenotype, proliferation, anchorage-independent growth, and mammosphere formation of breast cancer cells, as well as EGF-induced Ras-ERK and PI3K-Akt signaling pathways, downregulates HER2 expression, and induces cell death. CNBDA can be used in breast cancer-related research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > SHP2 | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Akt

Product Information

• Catalog No.: HY-156487
• CAS No.: 2101321-90-6
• Molecular Formula: C30H40O7
• Molecular Weight: 512.64
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source